Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Panelists flag counterfeit weight‑loss injectables, freight shipments and risky compounding
Loading...
Summary
Witnesses described three related threats: look‑alike counterfeits of GLP‑1 injectables, unregulated active pharmaceutical ingredients arriving in freight shipments, and sellers/telehealth companies offering unapproved compounded injectables. They urged stronger import screening and enforcement.
Witnesses testifying to the House Oversight Committee described multiple entry points by which counterfeit or unregulated weight‑loss medications and other pharmaceuticals have reached U.S. patients.
Shabir Imber Safdar, executive director of the Partnership for Safe Medicines, told the committee he sees three categories of risk: (1) look‑alike counterfeit injector pens that mimic brand devices but contain no active ingredient or contaminated components; (2) unapproved ‘‘research‑grade’’ active pharmaceutical ingredients that are sold on e‑commerce sites and through fake pharmacies and then used in compounding; and (3) freight shipments declared as made at implausible addresses or non‑inspected facilities that nevertheless entered U.S. ports.
Nut graf: Witnesses urged the committee to strengthen port‑of‑entry screening, improve verification of declared manufacturing sites, and increase enforcement against online sellers of untested ingredients. They also cautioned that compounded sterile injectables pose special risks when used outside established clinical indications.
Safdar described a counterfeit pen discovered by an Arkansas pharmacist; the Arkansas Board of Pharmacy used a barcode scanner app called Pulse to confirm the product was counterfeit and suspended the distributor’s license. He also reported freight shipments with implausible stated manufacturing origins, including hotel and gym addresses in Canada, that nonetheless entered the U.S.
Former FDA Commissioner David Kessler and other witnesses warned that the United States relies heavily on active pharmaceutical ingredients produced overseas, with one witness citing that roughly 80% of APIs come from China and India. Kessler said that lack of domestic production and weakened inspection capacity heighten the risk that counterfeit or contaminated drugs reach patients.
Ending: The panel recommended immediate attention to import screening, better verification of declared manufacturing sites, and stepped up criminal enforcement of online sellers and distributors. Committee members asked witnesses for further data and urged the agency to brief Congress on steps to block dangerous imports.
